Skip to main content

The Globe and Mail

CEO holdings tick up at ProMetic Life Sciences

Health care is the top performing TSX sector over the past 5 years, up more than 200 per cent, and the group is off to a strong start in 2014. ProMetic Life Sciences Inc. is one name that has been on our screens since last fall. The stock ranks in the top 30 per cent based on INK's criteria of valuations, insiders and price strength. In January, CEO Pierre Laurin added a net 80,000 shares to his holdings through options and public-market activity. Another Director bought 6,900 shares on Thursday at $1.42.

Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.

Infographic reflects public-market transactions of common shares or unit trusts by company officers and directors.

Story continues below advertisement

Report an error Editorial code of conduct
As of December 20, 2017, we have temporarily removed commenting from our articles. We hope to have this resolved by the end of January 2018. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.